USC Norris Comprehensive Cancer Center | Strategic Alliance Partners

September 14, 2020

A retrospective analysis of data from the CELESTIAL trial has demonstrated the potential role for cabozantinib in patients with advanced hepatocellular carcinoma and Child-Pugh B liver cirrhosis.

September 10, 2020

Heinz-Josef Lenz, MD, FACP, discusses optimal sequencing strategies for the treatment of patients with colorectal cancer.

August 17, 2020

Anthony B. El-Khoueiry, MD, discusses the frontline treatment landscape of hepatocellular carcinoma.

August 04, 2020

Renowned oncologist and cancer researcher will begin inaugural position in September.

September 25, 2019

Heinz-Josef Lenz, MD, FACP, discusses updated results from the phase II CheckMate-142 trial in metastatic colorectal cancer.

August 10, 2019

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses research on biomarkers in hepatocellular carcinoma (HCC).

July 26, 2019

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses immunotherapy combination in hepatocellular carcinoma (HCC).

July 19, 2019

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses choosing between immunotherapy agents and TKIs in hepatocellular carcinoma (HCC).

June 20, 2019

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses the role of ramucirumab in advanced hepatocellular carcinoma.

June 19, 2019

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses next steps with immunotherapy in metastatic colorectal cancer.

June 19, 2019

Anthony B. El-Khoueiry, MD, provides insight on the rapidly evolving treatment options in hepatocellular carcinoma.

June 12, 2019

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses frontline nivolumab plus ipilimumab in metastatic colorectal cancer.

June 12, 2019

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, distinguishes between lenvatinib and sorafenib for the frontline treatment of advanced hepatocellular carcinoma.

May 21, 2019

Bing Xia, MD, discusses the latest immunotherapy developments in nonsquamous non–small cell lung cancer, as well as sequencing strategies for patients with ALK-positive disease.

April 29, 2019

USC Norris Comprehensive Cancer Center has launched a study to determine how financial assistance for costs associated with clinical trial participation might increase enrollment, particularly among low-income patients and racial and ethnic minorities.

April 19, 2019

David I. Quinn, MD, PhD, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, Keck School of Medicine, discusses the current state of biomarkers in renal cell carcinoma.

April 05, 2019

David I. Quinn, PhD, MBBS, discusses the molecular diagnosis of renal cell carcinoma and also highlights emerging therapies in the treatment of patients with different subtypes of prostate cancer.

December 20, 2018

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the potential for immunotherapy in metastatic colorectal cancer.

December 07, 2018

Michael Pulsipher, MD, director of cellular therapy and stem cell transplantation, professor of pediatrics, USC Keck School of Medicine, discusses the role of MRD testing in pediatric patients treated with CAR T-cell therapy.

September 21, 2017

Heinz-Josef Lenz, MD, discusses his study of molecular variations between small bowel adenocarcinomas, right-sided colon cancers, and gastroesophageal cancers.